Compare FABC & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FABC | LPCN |
|---|---|---|
| Founded | N/A | 1997 |
| Country | United States | United States |
| Employees | 108 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 20.0M |
| IPO Year | 1999 | 2011 |
| Metric | FABC | LPCN |
|---|---|---|
| Price | $2.43 | $2.27 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 164.8K | 27.8K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,579,745.00 | $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $92.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $1.81 |
| 52 Week High | $4.57 | $12.37 |
| Indicator | FABC | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 53.45 |
| Support Level | N/A | $2.16 |
| Resistance Level | $2.98 | $2.30 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 11.82 | 48.77 |
Fabric.AI Inc is an infrastructure company building a suite of fabless semiconductor technologies to power AI factories - smart data centers optimized for producing intelligence at scale. The company's innovations include MicroLED-based optical interconnects and other system-critical technologies that enable faster, more efficient, and more scalable AI workloads. Its mission is to transform data centers into unified production systems for artificial intelligence.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.